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DOI 10.1016/j.ccr.2011.10.015SUMMARYTo identify FDA-approved agents targeting leukemic cells, we performed a chemical screen on two human
leukemic cell lines and identified the antimicrobial tigecycline. A genome-wide screen in yeast identifiedmito-
chondrial translation inhibition as the mechanism of tigecycline-mediated lethality. Tigecycline selectively
killed leukemia stem and progenitor cells compared to their normal counterparts and also showed antileu-
kemic activity in mouse models of human leukemia. ShRNA-mediated knockdown of EF-Tu mitochondrial
translation factor in leukemic cells reproduced the antileukemia activity of tigecycline. These effects were
derivative of mitochondrial biogenesis that, together with an increased basal oxygen consumption, proved
to be enhanced in AML versus normal hematopoietic cells and were also important for their difference in
tigecycline sensitivity.INTRODUCTION
Acute myeloid leukemia (AML) comprises a genetically and
clinically heterogeneous group of aggressive hematological
neoplasms characterized by clonal proliferation of malignant
precursors with a reduced capacity to differentiate into mature
cellular components (Lo¨wenberg et al., 1999). Although there
have been recent advances in the treatment of some hematolog-
ical malignancies, the therapy of AML has remained essentially
unchanged for over 20 years. For patients diagnosed when older
than 60, the prognosis is particularly poor, with a 2 year survivalSignificance
An important role of cytosolic translation has been well docum
ofmitochondrial translation in leukemia has not beenwell studi
thatmitochondrial translation inhibition selectively kills leukem
progenitors and stem cells. This may be attributable to the hig
Given these results and the known pharmacology and toxicol
lation inhibition as a therapeutic strategy in human leukemia is
674 Cancer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Incprobability of less than 10% (Lo¨wenberg et al., 1998). Thus,
further research is warranted into developing therapeutic strate-
gies for the treatment of this disease.
The anticancer effects of inhibiting cytoplasmic translation
have been previously reported, but the impact of inhibiting
mitochondrial translation is less well understood. Mitochondrial
DNA (mt-DNA) is composed of a double-stranded circular
genome 16.6 kb in length without introns (Lang et al., 1999). It
encodes 2 rRNAs, 22 t-RNAs, and 13 of the 90 proteins in the
mitochondrial respiratory chain. The 13 mt-DNA-encoded
proteins are translated by mitochondrial ribosomes within theented in the context of cancer, but the functional importance
ed. Here, we used chemical and genetic approaches to show
ic versus normal cells, including those defined functionally as
her rate of mitochondrial biogenesis found in leukemic cells.
ogy of tigecycline in humans, targeting mitochondrial trans-
attractive.
.
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2004; Zhang and Spremulli, 1998). Mitochondrial ribosomes
differ from eukaryotic cytosolic ribosomes in their structure
and chemical properties (O’Brien, 2003). In addition they use
unique protein translation machinery, including distinct initiation
and elongation factors.
To identify therapeutic strategies that target both leukemia
stem cells (LSCs) and bulk AML cells, we compiled a library of
on- and off-patent drugs, and screened these for their ability to
reduce the viability of leukemia cell lines that display the stem
cell properties of differentiation self-renewal, and marrow
engraftment. Based on the results of this screen, we investigated
the critical dependence of early- as well as late-stage primary
human AML cells on mitochondrial protein translation.
RESULTS
Chemical Screen for Compounds Targeting Leukemic
Cells Identifies the Antimicrobial Tigecycline
Because of their known toxicology and pharmacology, off- and
even on-patent drugs can be rapidly repurposed for new indi-
cations. To search among such compounds for those with
potential antihuman AML activity, we compiled a library of
312 such drugs focused mainly on antimicrobials and metabolic
regulators with well-characterized pharmacokinetics and toxi-
cology, and wide therapeutic windows. We then screened this
library to identify agents that reduced the viability of cells
from two human AML cell lines, TEX and M9-ENL1, that display
features of LSCs (see Figure S1 available online). These two
lines were chosen for our first screen because of their stem
cell properties, including hierarchal differentiation and self-
renewal (Barabe´ et al., 2007; Warner et al., 2005). Figure 1A
shows dose-response curves for five compounds that did not
have any previously recognized anticancer activity but dis-
played some antileukemic activity against at least one of these
two cell lines after a 72 hr period of exposure. Interestingly, sal-
inomycin was recently shown to have specific activity against
breast cancer stem cells (Gupta et al., 2009). The second
most active drug was tigecycline, which we then chose to
analyze further.
To determine the effect of tigecycline on a broader spectrum
of leukemia cell lines, a panel of human and murine leukemia
cells was similarly treated with increasing concentrations of
tigecycline. IC50 values ranging from 3 to 8 mM were obtained
for the various leukemia cell lines (Figure 1B). Tigecycline-
induced cell death was confirmed by Annexin V/PI staining
(Figure 1C). Of note, although tigecycline is a structural analog
of minocycline and tetracycline, TEX cells were not sensitive
to either minocycline or tetracycline at concentrations up to
25 mM (Figure 1B).
Tigecycline Kills Primary AML Bulk and Progenitor Cells
More Effectively than Normal Hematopoietic Cells
We next compared the ability of tigecycline to kill cells from 20
primary AML samples (18 from newly diagnosed patients and 2
from patients with relapsed, treatment-refractory disease; see
Table S1) and normal human hematopoietic cells within 48 hr
of exposure in vitro. Bulk low-density normal human hematopoi-
etic cells showed an LD50 of at least 10 mM, including the CD34
+Cancells isolated from two of these samples (Figure 1D). Cells from 7
of the 20 patients with AML studied displayed a similar sensitivity
to tigecycline (LD50 > 10 mM), but in the other 13 cases, a much
greater sensitivity to tigecycline was observed (LD50 < 5 mM). The
CD34+38 subset of AML progenitor cells was also similarly
sensitive to tigecycline (Figure S1). Notably, no differences in
cytogenetic risk or disease status were evident between the
sensitive and insensitive groups, and both of the samples from
relapsed, treatment-refractory patients were sensitive to
tigecycline.
To compare the effect of tigecycline on functionally defined
subsets of primitive human AML and normal hematopoietic cell
populations, additional experiments were performed. Incorpora-
tion of 5 mM tigecycline into the assay medium reduced the
clonogenic growth of primary AML patient samples (n = 7) by
93%± 4% (Figure 1E). In contrast, tigecycline had only aminimal
effect on the clonogenic growth of normal hematopoietic cells
assayed using the same protocol, including erythroid progeni-
tors (BFU-E) (n = 5). To assess the effects of tigecycline on
AML and normal hematopoietic stem cells, we treated primary
AML or normal Lin CD34+-enriched normal human hematopoi-
etic cord blood cells with 5 mM tigecycline or DMSO (as a control)
for 48 hr in vitro and then compared the number of human cells
produced after 6 weeks after transplantation into NOD/SCID
mice (eight mice per group). This tigecycline treatment protocol
reduced the repopulating ability of the primary AML cells tested
(p < 0.0001, Student’s t test) but had no effect on the repopulat-
ing activity of normal hematopoietic cells (Figure 1F).
Thus, for a majority of patients with AML, including some with
treatment-refractory disease, tigecycline effectively targets all
compartments of leukemic cells including the LSCs and does
so at concentrations that appear pharmacologically achievable
and that do not have a similar negative effect on normal hemato-
poietic cells.
Haplo-Insufficiency Profiling in S. cerevisiae Identifies
Mitochondrial Translation as Target of Tigecycline
in Eukaryotic Cells
Tigecycline is currently used clinically as a broad-spectrum anti-
biotic due to its high affinity and potent inhibition of the bacterial
ribosome (Olson et al., 2006; Stein and Craig, 2006). To deter-
mine the mechanism of tigecycline’s activity in eukaryotic cells,
we used haplo-insufficiency profiling (HIP), a well-validated
chemical genomics platform developed in the yeast
S. Cerevisiae. The HIP assay allows an unbiased in vivo quanti-
tative measure of the relative drug sensitivity of all 6000 yeast
proteins in a single assay, and results in a list of candidate protein
targets (Giaever et al., 1999; Hoon et al., 2008). Under standard
fermentation conditions in rich media (YP), where the primary
mode of metabolism is glycolysis, yeast growth was relatively
insensitive to tigecycline. In contrast, yeast grown in respiratory
conditions that depend on oxidative phosphorylation exhibited
increased sensitivity and dose-dependent inhibition by tigecy-
cline (Figure S2). Because growth inhibition is a necessary
criterion for the HIP assay, all subsequent experiments were
performed in respiratory media (YPGE).
The rank-ordered gene list of drug-sensitive strains generated
from the HIP assays was analyzed using Gene Set Enrichment
Analysis (GSEA) to identify Gene Ontology (GO) biologicalcer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Inc. 675
Figure 1. Chemical Screen for Compounds Targeting Leukemic Cells Identifies Antimicrobial Tigecycline
(A) Drugs were added to TEX and ENL-1 cells (three experiments each). Viability of cells after 72 hr was determined by MTS staining, and the results were
expressed as a percentage of matching DMSO-treated controls.
(B) TEX, human, and murine leukemia cells were incubated in triplicate experiments with drugs at concentrations shown for 72 hr. Viability was determined by
MTS (human cells) or ViaCount (murine cells) staining, and results were expressed as a percentage of results for untreated cells.
(C) TEX cells were exposed to 5 or 10 mM of tigecycline (TIG), and Annexin V staining by flow cytometry was used to discriminate viable cells. Data represent the
mean of Annexin V-positive cells from a representative experiment (n = 3).
(D) Primary AML (1 AML) (n = 20) and normal hematopoietic cells (n = 5) were treated with increasing concentrations of tigecycline for 48 hr. The proportion of
viable cells wasmeasured by Annexin-PI flow cytometry to calculate the yield of viable cells shown as percent viable DMSO-treated cells in the same experiment.
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Figure 2. HIP in S. cerevisiae Identifies Mitochondrial Translation as Target of Tigecycline in Eukaryotic Cells
(A) A pool of 6000 S. cerevisiae heterozygote mutant strains was cultured in the presence or absence of tigecycline, chloramphenicol (CAP), linezolid (LIN), or
doxorubicin (DOX) in YPGE media, and those showing altered growth responses relative to control cells were identified. GSEA processes are shown.
(B) Commonly enriched genes involved in mitochondrial translation identified from this GSEA are shown in the Venn diagram (B) and the heat map (C). Red color
denotes higher gene enrichment in the presence of drug relative to control cells.
See also Figure S2.
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most significantly enriched GO process was the mitochondrial
ribosome (p value < 0.0001; FDR q value < 0.005) (Figure 2A).
No other significant GO processes were enriched in the tigecy-
cline screen. In theHIP assay, when the target is a large complex,
no single gene in the complex stands out from the rest. For
comparison we also screened the known mammalian mitochon-
drial translation inhibitors chloramphenicol (McKee et al., 2006)
and linezolid (Nagiec et al., 2005), and the anthracycline family
member doxorubicin, which displays broad mechanisms of anti-
cancer activity (Swift et al., 2006; Tewey et al., 1984; Wallin et al.,
2010). Asexpected, chloramphenicol and linezolid yieldedsimilar
results to tigecycline, whereas the doxorubicin GO enrichment
analysis revealed a mechanism distinct from tigecycline (Figures
2B and 2C) (none of the doxorubicin GO terms passed our signif-
icance filter p value < 0.001; FDRq value 0.1). Taken together, the
yeast genomic screens suggest that tigecycline acts to inhibit
growth and viability of eukaryotic cells through interference with
mitochondrial protein translation. This finding is consistent with
tigecycline’s known ability to inhibit bacterial protein synthesis
by reversibly binding bacterial ribosomal RNA, thereby prevent-
ing docking of the tRNA with its codon into the A site of the ribo-
some complex (Olson et al., 2006).
Tigecycline Inhibits Mitochondrial Translation
in Established and Primary Leukemia Cells
To determine whether the specific toxicity of tigecycline on
leukemic cells is mediated by a similar mechanism, we next(E) Primary AML (n = 7) and normal hematopoietic cells (n = 5) were treated with 5
percentage of colonies obtained compared to DMSO-treated cells.
(F) Cells from a patient with AML and LinCD34+-enriched human cord blood cell
into femurs of irradiated NOD/SCID mice preconditioned with anti-CD122. Six w
measured by FACS. ***p < 0.0001, N.S., not significant, p > 0.05 as determined
Error bars represent mean ± SD.
See also Table S1 and Figure S1.
Canasked whether their exposure to tigecycline alters expression
of proteins whose translation is known to be dependent on
cytosolic and mitochondrial ribosomes. In a first set of experi-
ments, TEX, OCI-AML2, primary AML cells were incubated for
48 hr in increasing concentrations of tigecycline, and effects
on cytochrome c oxidase-1, 2, and 4 (Cox-1, 2, and 4, respec-
tively) levels were measured at the end of that time. Cox-1 and
Cox-2 are subunits of respiratory complex IV in the electron
transport chain in mitochondria and are translated by mitochon-
drial ribosomes (Tam et al., 2008). Cox-4 is a component of the
same respiratory complex but is encoded by the nuclear genome
and translated by nuclear ribosomes. Tigecycline treatment
caused a preferential decrease of Cox-1 and Cox-2 as com-
pared to Cox-4 (Figure 3A). Tigecycline also did not alter the
expression of other proteins translated by cytosolic ribosomes
including grp78 and the short half-life protein XIAP. The reduc-
tions in Cox-1 and Cox-2 protein levels were associated with
increases in their mRNA expression with less change in Cox-4
mRNA levels in the same cells. (Figure 3B) This result is consis-
tent with a previous report (Chrzanowska-Lightowlers et al.,
1994) in which inhibition of mitochondrial translation was
found to be accompanied by an increase in the expression of
mitochondrially encoded mRNA. Finally, we demonstrated that
tigecycline directly inhibits mitochondrial translation using
cell-free assays with mitochondria isolated from leukemia cells
(Figure 3C). Thus, taken together, our findings support a tigecy-
cline-mediated inhibition of mitochondrial translation as its
antileukemic cell mechanism of action.mM tigecycline and plated in clonogenic growth assays. Values shown are the
s were treated with 5 mM tigecycline or DMSO for 48 hr in vitro and then injected
eeks later, the percentage of human CD45+CD33+CD19 cells in femurs was
by the unpaired Student’s t test.
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Figure 3. Tigecycline Inhibits Mitochondrial Protein Translation
(A) Effects of increasing concentrations of tigecycline on protein levels of Cox-1, Cox-2, Cox-4, Grp78, XIAP, Actin, and tubulin in TEX, OCI-AML2, and two AML
patients’ cells treated for 48 hr.
(B) Effects of increasing concentrations of tigecycline on Cox-1, Cox-2, and Cox-4 mRNA expression in TEX and AML patient cells treated for 48 hr. Transcript
levels were determined by qRT-PCR and normalized relative to 18S. Data are shown as mean fold change compared to untreated controls (n = 3).
(C) Mitochondrial isolates from OCI-AML2 cells were treated with buffer control, tigecycline, or chloramphenicol for 5 min at 30C, followed by the addition of
[3H]-leucine. Incorporation of [3H]-leucine was measured after 60 min.
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affect the enzymatic activity of respiratory complexes I and IV,
both of which contain proteins translated on mitochondrial ribo-
somes, and by comparison to the respiratory chain complex II,
which does not contain mitochondrially encoded subunits in its
substructure (Ott and Herrmann, 2009). Tigecycline significantly
decreased the enzyme activity of respiratory complexes I and
IV but had less effect on the enzymatic activity of the complex II
(Figure3D). Thesefindingsweremirroredby treatmentwith chlor-
amphenicol, a known mitochondrial protein synthesis inhibitor.
Consistent with its effects on themitochondrial respiratory chain,
tigecycline decreased oxygen consumption in TEX and primary
AML, but not normal hematopoietic cells at concentrations asso-
ciated with, but at times preceding, cell death (Figure 3E).
Themitochondrial respiratory chaingenerates anelectrochem-
ical protongradient that establishes themitochondrialmembrane
potential (Ramzan et al., 2010) used to drive ATP generation by
complex V (ATP synthase). Therefore, we examined the effect
of tigecycline treatment on themitochondrialmembranepotential
as determined by staining with the carbocyanine dye JC-1
(Smiley et al., 1991). TEX cells and three different primary AML
samples showed adecreasedmitochondrialmembranepotential
after tigecycline treatment (5 mM), at times preceding the onset of
cell death (Figure 3F). In contrast loss ofmitochondrialmembrane
potential was not seen in normal hematopoietic cells from after
a similar in vitro incubationwith tigecycline. Thepreferential effect
of tigecycline on collapsing the membrane potential of leukemia
cells may help explain the preferential cytotoxicity of tigecycline
for AML cells over normal cells.
A by-product of the mitochondrial electron transport chain is
the generation of reactive oxygen species (ROS). Respiratory
chain inhibitors such as rotenone and Na azide have been
previously shown to induce rapid increases in ROS generation
leading to cell death (Li et al., 2003; Park et al., 2007; Turrens
and Boveris, 1980). Therefore, we explored the role of tigecycline
on ROS generation in leukemia cells. Tigecycline did not
increase ROS generation in TEX cells at time points up to 24 hr
(Figure S3). In contrast various mitochondrial complex enzyme
inhibitors produced rapid increases in ROS levels (Figure S3).
Therefore, we postulate that the kinetics of tigecycline-induced
inhibition of mitochondrial translation and respiratory complex
activity produce functional effects distinct from agents that
inhibit or uncouple the respiratory chain.
Inhibition of Mitochondrial Translation Is Functionally
Important for the Selective Toxicity of Tigecycline
on Leukemia Cells
To determine whether tigecycline’s effects on the viability of
leukemia cells are dependent on inhibition of mitochondrial(D) Effect of increasing concentrations of tigecycline and chloramphenicol on com
treated for 72 hr. Values shown are average of three independent experiments.
analysis.
(E) Oxygen consumptionwasmeasured in TEX, AMLpatient, and normal hematop
1.2 mM oligomycin. Values shown are average of three independent experiments
(F) Effect of increasing concentrations of tigecycline onmitochondrial membrane
12 or 24 hr and then stained with JC-1 dye for flow cytometry. Shown are the
a percentage of that in DMSO-treated control cells from the same experiments (
Error bars represent mean ± SD.
See also Figure S3.
Canfunction, we evaluated its antileukemic activity under different
conditions of hypoxia (20%–0.2% O2) and anoxia (0% O2) (Fig-
ure 4A). Incubation of both TEX and primary AML cells under
anoxic conditions alone was toxic and in parallel reduced the
mitochondrial membrane potential in these cells (Figures 4A
and 4B). However, coexposure to tigecycline under anoxic
conditions caused no further cell loss, and changes in mito-
chondrially translated COX subunits I and II, determined by
immunoblotting 48 hr after tigecycline treatment, were no longer
evident (Figure 4C). Nevertheless, these experiments demon-
strated that tigecycline remained active against leukemia cells
and primary patient AML samples under oxygen concentrations
of 1%–5% that are present in the bone marrow of patients with
AML (Fiegl et al., 2009). Taken together, these results demon-
strate that the ability of tigecycline to kill leukemia cells is
dependent on oxygen availability and an intact mitochondrial
respiratory chain.
We next assessed tigecycline sensitivity of leukemic cells with
genetically altered mitochondrial biogenesis. Previous studies
have shown that Myc plays an important role in promoting
mitochondrial biogenesis in a Burkitt’s lymphoma model (Li
et al., 2005). Consistent with previous reports, inducible repres-
sion of Myc in p493 Burkitt’s cells resulted in decreased mito-
chondrial mass (p < 0.05, t test) (Figures 4D and 4E), mt-DNA
copy number (p < 0.005, t test) (Figure 4F), and oxygen con-
sumption rate (p < 0.005, t test) (Figure 4G). Furthermore, Myc-
repressed p493 cells with decreased mitochondrial mass were
sensitive to hypoxia conditions, highlighting their dependence
on oxidative metabolism (Figure 4H). We used these cells to
evaluate the effects of reduced mitochondrial biogenesis on
the cytotoxicity of tigecycline. Tigecycline treatment reduced
the growth and viability of control p493 cells with functional
Myc. In contrast, p493 cells with decreased mitochondrial
mass followingMyc repression were resistant to tigecycline (Fig-
ure 4I). These results further support the notion that tigecycline’s
antileukemic mechanism of action is dependent on inhibition of
mitochondrial function. However, we recognize that Myc repres-
sion can affect processes beyond mitochondrial biogenesis
including cell cycle and nonmitochondrial translation that may
also impact sensitivity to tigecycline.
Genetic and Chemical Inhibition of Mitochondrial
Translation Displays Antileukemia Properties
To further explore the antileukemic activity of mitochondrial
translation inhibition, we askedwhether genetic strategies would
produce similar antileukemic effects as seen with tigecycline.
Protein translation in mitochondria is regulated by a series of
initiation and elongation factors specific to this organelle (Spre-
mulli et al., 2004). Mitochondrial Initiation Factor 3 (IF-3) playsplex I, II, and IV enzyme activities relative to citrate synthase activity in TEX cells
*p < 0.05, **p < 0.005, as determined by Tukey’s test after one-way ANOVA
oietic cells treated for 12 or 24 hr with tigecycline. The arrows denote addition of
.
potential (Dc) in TEX, AML patients’, and normal hematopoietic cells treated for
average Red/Green ratios derived for tigecycline-treated cells expressed as
n = 3 per cell type).
cer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Inc. 679
Figure 4. Inhibition of Mitochondrial Translation Is Functionally Important for Tigecycline-Induced Death of Leukemia Cells
(A) TEX and primary AML cells were treated under different oxygen concentrations for 48 hr. Viability (Annexin-PI) and mitochondrial membrane potential.
(B) (Dc, Red/Green ratio of JC-1) were assessed by flow cytometry. Results are shown relative to DMSO-treated control.
(C) Total proteins were extracted from TEX cells and analyzed by immunoblotting for Cox1, Cox2, Cox4, and tubulin.
(D) p493 lymphoma cells carrying a tetracycline-repressible human Myc construct were cultured in the presence and absence of 0.1 mg/ml (0.22 mM) of tetra-
cycline for 96 hr. Total proteins were extracted and analyzed by immunoblotting for Myc and actin.
(E) Mitochondrial mass was measured by incubating cells with MitoTracker Green FM dye, and subsequent flow cytometry. Median fluorescence intensity is
shown relative to wild-type p493 cells.
(F) DNA was extracted from cells, and quantitative PCR was used to measure levels of mitochondrial ND1 relative to human globulin (HGB). ND1/HGB ratio is
shown relative to wild-type p493 cells.
(G) Oxygen consumption was measured and is shown after 15 min incubation in cell chambers. *p < 0.05, **p < 0.005 as determined by unpaired Student’s t test.
(H) p493 cells with or without repressed Myc were plated in different oxygen concentrations (20%, 0.2%, and 0%) for 72 hr. The proportion of viable cells was
measured by Annexin-PI flow cytometry and calculated as the percentage of viable cells compared to 20% oxygen control condition.
(I) p493 cells with or without repressedMYCwere washed and then treated with increasing concentrations of tigecycline for 48 hr. After treatment, the number of
viable cells was determined by trypan blue staining. Data represent the mean number of viable cells from one of three independent experiments.
Error bars represent mean ± SD.
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tian and Spremulli, 2009). Mitochondrial elongation factor Tu
(EF-Tu) is responsible for bringing aminoacyl-tRNAs in complex
with GTP to the decoding site on the mitochondrial ribosome
(Spremulli et al., 2004). We evaluated the effects of lentiviral
vector-mediated shRNA knockdown of IF-3 or EF-Tu in TEX
cells. Target knockdown was confirmed by qRT-PCR and immu-
noblotting using two independent shRNAs for each gene
(Figures 5A and 5B). Compared to control shRNA, knockdown
of EF-Tu increased mRNA expression and decreased protein680 Cancer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Incexpression of Cox-1 and Cox-2 (Figures 5C and 5D) but did
not change Cox-4 protein or mRNA levels. Similar to tigecycline,
EF-Tu knockdown reduced the growth and viability of TEX cells
(Figure 5E), and was associated with decreased mitochondrial
membrane potential and oxygen consumption (Figures 5F and
5G), with no change in ROS production (Figure S4). In contrast
to the effects of EF-Tu knockdown, IF-3 knockdown did not
alter levels of Cox-1 and Cox-2 protein and mRNA (Figures 5C
and 5D), did not reduce mitochondrial membrane potential or
oxygen consumption (Figures 5F and 5G), and did not alter the.
Figure 5. Alternative Genetic and Chemical Strategies to Inhibit Mitochondrial Translation Have Antileukemia Effects
(A) TEX cells were infected with EF-Tu or IF-3 targeting shRNAs or control sequences in lentiviral vectors. Six days post-transduction, EF-Tu and IF-3 mRNA
expression relative to 18S (A) and protein expression determinations (B) were made by qRT-PCR and immunoblotting, respectively.
(C) Effects on mRNA expression of Cox-1, Cox-2, Cox-4, and tubulin were determined by qRT-PCR using 18S RNA as an internal standard (one of three
representative experiments shown).
(D) Effects on expression of Cox-1, Cox-2, Cox-4, and tubulin protein were determined by immunoblotting (a representative experiment is shown).
(E) Viable cells were measured by trypan blue staining and cell death by Annexin-V staining. Data from one of three independent experiments are shown.
Additional cells treated in the same way were used to measure effects on other parameters.
(F) Effects on mitochondrial membrane potential (Dc) were determined by staining cells with the JC-1 dye and then determining Red/Green ratios by flow
cytometric analysis.
(G) Effects on oxygen consumption were determined as described in the Supplemental Experimental Procedures. Arrows denote addition of 1.2 mM oligomycin.
Results for one of two experiments with similar outcomes are shown.
Error bars represent mean ± SD.
See also Figure S4.
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Mitochondrial Translation Inhibition in Leukemiacell growth and viability of TEX cells (Figure 5E). These results
support inhibition of mitochondrial translation as a therapeutic
strategy against human leukemic cells. These results also
demonstrate that some but not all components of the mitochon-
drial protein translation machinery are necessary to maintain
mitochondrial translation.
To further assess the possibility that other strategies of inhib-
iting mitochondrial translation might also have antileukemic
potential, we treated TEX leukemia cells with increasing con-
centrations of chloramphenicol and linezolid, compounds known
to inhibit mitochondrial translation in mammalian cells at high
concentrations in vitro (McKee et al., 2006; Nagiec et al.,
2005). A 4 day incubation with either agent decreased the
viability and proliferation of TEX cells, but at higher drug concen-
trations than required for tigecycline-induced killing (Figure S4).
Both drugs also reduced expression of mitochondrially trans-
lated Cox-1 and Cox-2 subunits but did not affect levels of
Cox-4. Furthermore, chloramphenicol (50 mM) reduced the clo-
nogenic growth of cells from two primary AML patient samples
to a greater degree than that of normal hematopoietic progeni-
tors. These results suggest that tigecycline is a more potent
inhibitor of mammalian mitochondrial ribosomes compared to
chloramphenicol or linezolid, consistent with its more potent
inhibition of bacterial protein synthesis (Contreras and Va´zquez,
1977; Olson et al., 2006; Shinabarger et al., 1997), and provide
an explanation for tigecycline’s selective antileukemic effects
at pharmacologically achievable concentrations. Overall, our
findings in these chemical and genetic experiments validate
inhibition of mitochondrial translation as a plausible therapeutic
strategy for AML.
AML Cells Have Increased Mitochondrial Biogenesis
and Basal Oxygen Consumption Compared
to Normal Hematopoietic Cells
To investigate the basis of leukemic cell hypersensitivity to
mitochondrial translation inhibition, we assessed baseline mito-
chondrial characteristics of primary normal hematopoietic and
AML cells. There was no difference in resting mitochondrial
membrane potential between leukemic and normal hematopoi-
etic progenitor cells that could account for their differential sensi-
tivity to tigecycline (Figure 6A). We then evaluated mt-DNA copy
number, which has previously been used as an estimate of mito-
chondrial mass (Xing et al., 2008) and the energy demand of
a cell (Capps et al., 2003). Cells from seven patients with AML,
including both CD34+/CD38+ and CD34+/CD38 subsets, had
highermt-DNA copy number compared to normal hematopoietic
cells (Figure 6B). Determination of mitochondrial mass using
MitoTracker Green FM, which stains mitochondria regardless
of resting mitochondrial membrane potential (Pendergrass
et al., 2004), again showed higher values for the AML cells (n =
5) than for normal CD34+ hematopoietic cells (n = 6) (Figure 6C),
including both the CD34+/CD38+ and CD34+/CD38 subsets of
leukemic cells (Figure 6D). Consistent with these findings, rates
of oxygen consumption were higher in primary AML cells (n = 4)
compared to normal hematopoietic cells (n = 5) (Figure 6E).
To investigate whether baseline mitochondrial mass differ-
ences in AML patient samples are related to their in vitro hyper-
sensitivity to tigecycline, baseline mitochondrial mass measure-
ments were performed on the leukemic cells from nine patients682 Cancer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Incwith AML and compared to their individual sensitivities to 5
and 10 mM tigecycline (Figure 6F). Mitochondrial mass was
significantly negatively correlated with in vitro sensitivity to tige-
cycline after 48 hr (5 mM dose, r = 0.71, p < 0.05; 10 mM dose,
r =0.69, p < 0.05, Pearson correlation). Thus, samples with the
greatest mitochondrial mass were most sensitive to tigecycline
treatment in vitro. Taken together, these results suggest that
AML progenitors and stem cells are more metabolically active
and dependent onmitochondrial function than are normal hema-
topoietic cells, and provide amechanism to explain the observed
differential activity of mitochondrial translation inhibition in
leukemic and normal hematopoietic cells at all levels of differen-
tiation (Figure 1D).
Tigecycline Shows Anti-AML Activity in Xenograft
Models of Human Leukemia
To assess the in vivo antileukemia efficacy of mitochondrial
translation inhibition using xenograft models, we first evaluated
the pharmacokinetics of tigecycline in mice (Figure S5). Based
on these studies, we chose a treatment schedule of twice-daily
intraperitoneal (i.p.) injections. In a first experimental design,
OCI-AML2 cells were transplanted subcutaneously into severe
combined immune deficiency (SCID) mice, and treatment was
started 7 days later when tumors were already palpable (eight
mice per group). Compared to the vehicle control, tigecycline
significantly delayed tumor growth and showed equivalent or
greater potency than daunorubicin or bortezomib at their maxi-
mally tolerated doses (Figure 7A) (p < 0.005, Tukey’s t test after
one-way ANOVA). Treatment with tigecycline did not alter the
appearance or behavior of themice. Moreover, at the conclusion
of the experiment 3 weeks post-transplant, there were no gross
changes to the organs at necropsy. Tumors excised from mice
treated for 5 days with tigecycline (50 mg/kg b.i.d.) showed
a greater reduction of expression of mitochondrially translated
Cox-1 and Cox-2 relative to nuclear-translated Cox-4,
compared to vehicle-treated controls (Figure 7B). Thus, tigecy-
cline inhibits growth and mitochondrial function of this AML
cell line in vivo.
Xenotransplantation in NOD/SCID mice is a robust model
system to assay stem cells and test the efficacy of antileukemia
therapies in vivo (Bonnet and Dick, 1997; Jin et al., 2006; Lapidot
et al., 1994). We transplanted preconditioned NOD/SCID mice
intra-femorally with primary AML cells from three patients and
Lin CD34+-enriched human cord blood cells, and then evalu-
ated the effects of a 3 week course of tigecycline started 3weeks
post-transplant (ten mice per group). Tigecycline-treated mice
had significantly lower levels of leukemic engraftment compared
to control-treated mice without evidence of toxicity (Figure 7C)
(p < 0.005, Student’s t test). Treatment with tigecycline did not
alter the appearance or behavior of the mice nor produce gross
changes to the organs at necropsy. There were also no alter-
ations in serum levels of liver or muscle/cardiac enzymes
(Figure S5).
Importantly, leukemic cells harvested from the bone marrow
of tigecycline-treated primary mice generated smaller leukemic
grafts in untreated secondary mice, compared to cells harvested
from control-treated primary mice (Figure 7D) (p < 0.05,
Student’s t test), indicating that tigecycline was active against
AML stem cells. In contrast, tigecycline treatment in vivo did.
Figure 6. Mitochondrial Characteristics of AML and Normal Hematopoietic Cells
(A) Baseline mitochondrial membrane potential values for AML and normal CD34+ cells before and after uncoupling the potential with CCCP, as determined by
staining the cells with DilC1 (5).
(B) Left panel shows mt-DNA copy number determined in seven patients with AML and six normal hematopoietic samples. Right panel shows mt-DNA copy
number determined in a primary AML sample after CD34+ and CD38+ fluorescence-activated cell sorting and two normal hematopoietic samples. DNA was
extracted from cells, and quantitative PCR was performed for mitochondrial ND1 relative to human globulin (HGB). The ND1/HGB ratio is shown relative to cells
from one normal sample.
(C and D) Mitochondrial mass values for AML blasts (C), CD34+/CD38+ cells, and CD34+/CD38 cells (D), and normal CD34+ cells were determined by flow
cytometric analysis of cells stainedwithMitoTracker Green FM.Median fluorescence intensity (MFI) values are shown by comparison to theMFImeasured for one
of the normal samples.
(E) Comparison of resting oxygen consumption rates of primary AML cells (n = 4) and normal hematopoietic cells (n = 5).
(F) Correlation analysis of mitochondrial mass (MitoTracker Green FM staining) and in vitro toxicity to tigecycline (Annexin-V/PI staining) of primary AML cells
(n = 11) based on results obtained at doses of 5 and 10 mM. *p < 0.05, as determined by Pearson correlation coefficient.
Error bars represent mean ± SD.
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preferential activity against LSCs over normal hematopoietic
cells (Figure 7E).
We also evaluated the efficacy of tigecycline in combination
with daunorubicin or cytarabine, two standard chemotherapeutic
agents used for the treatment of AML. TEX and OCI-AML2
leukemia cells were treated in vitro with increasing concentra-
tions of tigecycline alone or in combination with daunorubicin
or cytarabine, andgrowth andviabilitywereassessed (Figure 8A).
Data were analyzed using the Calcusyn median effect model,
where the combination index (CI) indicates synergism (CI < 0.9),
additivity (CI = 0.9–1.1), or antagonism (CI > 1.1). Tigecycline
and daunorubicin added together showed an additive or syner-Cangistic effect (CI = 0.75–1.0). However, when tigecycline was
added either before or after daunorubicin, the combination was
clearly synergistic (CI values at ED50 < 0.8). Treatment with
tigecycline in combination with cytarabine was additive or syner-
gistic (CI = 0.75–1.3), regardless of drug sequence. We then
tested the efficacy of the tigecycline/daunorubicin and tigecy-
cline/cytarabine combinations in the OCI-AML2 xenograft model
(eight mice per group). Mice treated with the two drug combina-
tions showed reduced tumor growth by comparison to those
receiving single agents (Figure 8B) (p < 0.005, Tukey’s t test after
one-wayANOVA). Combination treatments did not alter thegross
histology of heart, muscle, brain, spleen, and kidney (Figure S6).
There were also no alterations in serum levels of liver or muscle/cer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Inc. 683
Figure 7. Tigecycline Has In Vivo Activity in Models of Human Leukemia in Mice
(A) Human leukemia (OCI-AML2) cells were injected subcutaneously into the flank of SCIDmice. Seven days later, when tumors were palpable, mice were treated
with tigecycline (50 or 100 mg/kg twice daily by i.p. injection), bortezomib (1 mg/kg t.i.w.), daunorubicin (0.65 mg/kg t.i.w.), or vehicle control (n = 10 per group).
Three weeks after injection of cells, mice were sacrificed, tumors excised, and the volume andmass of the tumors weremeasured. The tumormass and themean
volume are shown. **p < 0.005, as determined by Tukey’s test after one-way ANOVA analysis.
(B) Tumors from two control (CTL) mice and three tigecycline (TIG)-treated mice were excised after 5 days of treatment, and total proteins were extracted and
analyzed by immunoblotting for Cox-1, Cox-2, Cox-4, and tubulin.
(C) Primary cells from three patients with AML and Lin CD34+-enriched human cord blood cells (E) (Normal) were injected intra-femorally into irradiated female
NOD/SCID mice. Three weeks after injection, the mice were treated with tigecycline (100 mg/kg by i.p. injection daily) or vehicle control (n = 10 per group) for
three weeks. Following treatment, human leukemia cell engraftment in the femur was measured by flow cytometric analysis of human CD45+CD19CD33+ cells.
**p < 0.005 as determined by Student’s t test.
(D) Cells frommice transplanted with one AML patient experiment were used to assess secondary engraftment in a second generation of NOD/SCID mice. Equal
numbers of viable leukemia cells from the bonemarrow of control and tigecycline-treated mice were pooled and aliquots injected into irradiated NOD/SCIDmice,
which were not treated with tigecycline. Six weeks later, human leukemia cell engraftment in the femur was measured by flow cytometric analysis for human
CD45+CD19CD33+ cells. Line represents median of engrafted human cells.
*p < 0.05, N.S., not significant, p > 0.05 as determined by Student’s t test.
Error bars represent mean ± SD.
See also Figure S5.
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Figure 8. Tigecycline Has In Vivo Antileukemia Activity in Combination with AML Agents Daunorubicin and Cytarabine
(A) The effect of a 72 hr exposure of TEX and OCI-AML2 cells to different concentrations of tigecycline in combination with daunorubicin or cytarabine on the
viability of the cells wasmeasured byMTS assay after 72 hr of incubation. Data were analyzedwith Calcusyn software to generate a CI versus fractional effect (cell
death) plot showing the effect of the combination of tigecycline with daunorubicin or cytarabine. CI < 1 indicates synergism.
(B) Human leukemia (OCI-AML2) cells were injected subcutaneously into the flank of SCID mice. Six days after injection, when tumors were palpable, mice were
treated with tigecycline (50 mg/kg daily by i.p. injection) and/or daunorubicin (0.65 mg/kg t.i.w. by i.p. injection) and/or cytarabine (10 mg/kg daily by i.p. injection)
or vehicle control (seven mice per treatment group). Another 2 weeks later, mice were sacrificed, tumors excised, and the volume and mass of the tumors were
measured and mean values determined. The tumor mass and the mean volume are shown. *p < 0.05, **p < 0.005, as determined by Tukey’s test after one-way
ANOVA analysis. Error bars represent mean ± SD.
See also Figure S6.
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therapy with tigecycline may enhance the antileukemic efficacy
of standard chemotherapeutic agents in patients.
DISCUSSION
One approach to develop therapies for AML is to target both the
LSCs and bulk AML cells. Here, we report that the antimicrobial
tigecycline has toxicity for human AML cells at all stages of
development in both in vitro and in vivo preclinical models, while
sparing normal hematopoietic cells. In addition we provide
detailed evidence that this drug acts by inhibiting mitochondrial
translation because of a dependence of leukemic cells on this
aspect of cell behavior.
Tigecycline is an antimicrobial agent of the glycylcycline class
and is active against a range of Gram-positive and Gram-nega-
tive bacteria, particularly drug-resistant pathogens (Stein and
Craig, 2006). From a screen of the effects of tigecycline on yeast
mutants that cover most of the yeast genome, we correctly
identified the inhibition of mitochondrial-based translation as
the mechanism used by tigecycline to inhibit eukaryotic cells.
This finding, in turn, led to our discovery that leukemic cells
owe their heightened sensitivity to tigecycline due to an in-
creased dependence on mitochondrial function. These results
underscore the incredible power of yeast screens to reveal
critical pathways that underlie effects seen in drug screens.
To interrogate the role of mitochondrial functions in leukemic
cells and their potential for specific antileukemic targeting strat-
egies, we used a combination of genetic, chemical, biochemical,
and biologic approaches. Knockdown of initiation (IF-3) and
elongation (EF-Tu) factors in leukemia cells provided genetic
confirmation of the prediction that specific inhibition of mito-
chondrial translation in leukemic cells would mimic the effects
of tigecycline, although IF-3 knockdown did not. Currently, it is
not fully understood why IF-3 knockdown does not inhibit mito-
chondrial translation. IF-3 stimulates mitochondrial translation
by altering the ribosomal subunit dissociation equilibrium and
does not directly stimulate the binding of tRNA molecules (Koc
and Spremulli, 2002). We speculate that in the absence of IF-3,
functional translation still occurs due to compensation by other
members of the translation machinery. Thus, some factors
involved in mitochondrial translation appear more critical than
others for the integrity of this process. Accordingly, future inves-
tigations exploring the possible role of mitochondrial translation
in other cancers will also likely need to assess the functional
importance of various initiation and elongation factors.
The impact of inhibiting mitochondrial protein synthesis and
the oxidative phosphorylation pathway in leukemia has not
been fully assessed. Interestingly, the 13 mt-DNA-encoded sub-
units of the electron transport chain are important for functional
regulation of oxidative phosphorylation (Fukuda et al., 2007). The
Warburg hypothesis proposes that malignant cells rely on glycol-
ysis and are significantly less dependent on oxidative phosphor-
ylation for survival (Warburg, 1956). Yet, more recent studies
indicate that some tumors are highly dependent on oxidative
phosphorylation for survival (Funes et al., 2007; Moreno-Sa´n-
chez et al., 2007; Rodrı´guez-Enrı´quez et al., 2006). Our data
suggest that LSCs are unique in their mitochondrial characteris-
tics, sensitivity to inhibition of mitochondrial protein synthesis,686 Cancer Cell 20, 674–688, November 15, 2011 ª2011 Elsevier Incand their reliance on oxidative phosphorylation. Recently, it
was demonstrated that leukemia cells have increased rates of
fatty acid oxidation (Samudio et al., 2010), and inhibition of fatty
acid oxidation targeted both LSCs and their ‘‘mature’’ blast
progeny. These findings complement those we now report. Elec-
trons generated from the oxidation of fatty acids ultimately flow
through the mitochondrial respiratory chain. As such, reducing
the components of the mitochondrial respiratory chain via mito-
chondrial translation inhibition would limit the ability of leukemia
cells to derive energy from fatty acid oxidation, thus offering an
explanation of how inhibition of either of these processes might
specifically constrain the survival or growth of leukemic cells.
The differences in the mitochondrial characteristics of primary
AML cells and their normal counterparts are also noteworthy.
AML bulk, stem cells, and their progeny had a greater mitochon-
drial mass and higher rates of oxygen consumption compared to
normal hematopoietic progenitor cells as shown by multiple
endpoints. Notably, AML CD34+/CD38+ and bulk subsets had
higher mitochondrial mass than CD34+/CD38 cells, reflecting
the metabolic differences in rapidly diving AML blasts. However,
all AML subsets had notably higher mitochondrial mass than
normal hematopoietic cells. Moreover, AML cells with the high-
est mitochondrial mass were the most sensitive to tigecycline,
suggesting a biological correlation between these two parame-
ters. The fact that normal hematopoietic cells have a low mito-
chondrial mass is consistent with this finding and may explain
the general preferential sensitivity of AML cells to inhibition of
mitochondrial protein synthesis. Although this correlation does
not imply a cause and effect relationship, mitochondrial mass
may serve to identify potential subgroups of patients with AML
most likely to respond to a therapeutic strategy that targets
their functions. The robust preclinical antileukemia activity docu-
mented with tigecycline using a variety of in vitro and in vivo
models and its known toxicology and pharmacology in humans
and animals support rapidly advancing this drug into clinical trial
for leukemia to evaluate proof of mechanism and proof of
concept. In conclusion a combination of small molecule screens
and yeast mutant screens, coupled with follow-up studies of
primary AML cell responses in vitro and in vivo, has enabled
mitochondrial translation inhibition to be identified as a thera-
peutic target for human AML with the antimicrobial tigecycline
as a lead candidate. Investigation of the mechanistic basis of
the selective sensitivity of AML cells to agents that inhibit
this process has revealed an elevated state of mitochondrial
biogenesis in AML cells upon which AML cells at all stages of
differentiation apparently depend. Thus, despite the genetic
and biological diversity of spontaneously arising human AML
clones, some common biochemical pathways accessible to
selective targeting appear to still exist and await therapeutic
exploitation.
EXPERIMENTAL PROCEDURES
Detailed experimental procedures are available in the Supplemental Experi-
mental Procedures.
Primary AML and Normal Hematopoietic Cells
Primary human AML samples were isolated from peripheral blood samples
from consenting patients with AML, who had at least 80% malignant cells
among the low-density cells isolated by Ficoll density centrifugation. Primary.
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consenting volunteers donating peripheral blood stem cells for allogeneic
stem cell transplantation after G-CSFmobilization. Primary cells were cultured
at 37C in IMDM, supplemented with 20% fetal bovine serum (FBS), and
appropriate antibiotics. The collection and use of human tissue for this study
were approved by the University Health Network institutional review board
and Review Ethics Board of the University of British Columbia.
Yeast Genomic Screen
To identify the primary mechanism of drug action, HIP in yeast was used
to profile the fitness of 6000 heterozygous deletion strains (Giaever et al.,
2004; Smith et al., 2010) in the presence of our compounds. Because wild-type
yeast growth was more sensitive in respiratory media, the yeast heterozygous
deletion pools were grown in YP media supplemented with 2% glycerol and
1% ethanol. The fitness assay on the deletion strains was performed as
described (Pierce et al., 2006) with the following modifications: (1) for barcode
amplification, 0.2 mg of genomic DNAwas used in a 50 ml PCR containing 1 mM
mix of up- or down-tag primers and 82% (v/v) of High Fidelity Platinum PCR
SuperMix (Invitrogen, Carlsbad, CA); (2) 34 amplification cycles were used
for the PCR using an extension temperature of 68C for 2 min except for a final
10 min in the last cycle; and (3) after 10–16 hr of hybridization, the arrays were
washed in a GeneChip Fluidic Station 450 (Affymetrix, Santa Clara, CA) using
the GeneFlex_Sv3_450 protocol with one additional wash cycle before the
staining. The Affymetrix GeneChip Command Console Software was used to
extract the intensity values from the arrays, and the fitness defects were calcu-
lated for each deletion strains as log2 ratios (mean signal intensity of control/
mean signal intensity of drug).
Yeast Growth Rate Measurements
The growth rate of wild-type yeast (Giaever et al., 2002) was determined by
measuring the ratio of the area under the curve (AUC) after 20 generations of
growth plus drug to AUC in vehicle alone (2% DMSO).
Assessment of Tigecycline’s Antileukemia Activity in MouseModels
of Human Leukemia
All animal studies were carried out according to the regulations of the
Canadian Council on Animal Care and with the approval of the Ontario Cancer
Institute Animal Ethics Review Board. Tumor xenograft (OCI-AML2) experi-
ments were performed using SCID mice. Primary AML and normal cord
blood engraftment in the mouse bone marrow was performed using irradiated
NOD-SCID mice. Details on mouse models and subsequent analysis can be
found in Supplemental Experimental Procedures.
Statistical Analysis
All data are expressed as mean and standard deviation (SD) to indicate data
variability. Statistical analyses were performed by unpaired Student’s t test,
one-way ANOVA, and post hoc Tukey’s test, as indicated. Differences were
considered statistically significant at p < 0.05.
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